LCM
GPCR icon

Lynx1 Capital Management’s Structure Therapeutics GPCR Stock Holding History

Lynx1 Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23,000
Closed -$956K – 22
2023
Q2 		$956K Hold
23,000
– – 0.63% 14
2023
Q1 		$547K Buy
+23,000
New +$540K 0.46% 12

Other funds holding GPCR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Lynx1 Capital Management's GPCR Position: Q3 2023 in Review

Lynx1 Capital Management sold out of Structure Therapeutics (GPCR) in Q3 2023, closing a stake of 23,000 shares — an estimated $956K sold.

Lynx1 Capital Management first reported a position in GPCR in Q1 2023 and held it in 2 quarters. The position peaked at $956K in Q2 2023. 84 funds tracked by Wall St. Rank hold GPCR as of Q3 2023.

  • Lynx1 Capital Management reported no remaining Structure Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Lynx1 Capital Management sold 23,000 Structure Therapeutics shares in Q3 2023, an estimated $956K.
  • Lynx1 Capital Management first reported a position in Structure Therapeutics in Q1 2023 and held it in 2 quarters.
  • Lynx1 Capital Management's Structure Therapeutics position peaked at $956K in Q2 2023.
  • 84 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2023.

Based on Lynx1 Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.